National Guideline Clearinghouse | The use of bevacizumab in metastatic breast cancer.

Guideline Title
The use of bevacizumab in metastatic breast cancer.

Bibliographic Source(s)
Dent R, Haynes AE, Enright K, Hamm C, Trudeau M, Eisen A. The use of bevacizumab in metastatic breast cancer. Toronto (ON): Cancer Care Ontario (CCO); 2009 Apr 17. 24 p. (CED-CCO special advice report; no. 12). [24 references]

Guideline Status

This is the current release of the guideline.

Please visit the Cancer Care Ontario Web site [http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=45745]External Web Site Policy for details on any new evidence that has emerged and implications to the guidelines.

full-text:
National Guideline Clearinghouse | The use of bevacizumab in metastatic breast cancer.





Program in Evidence-based Care

▲ * First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer.
[National Guideline Clearinghouse | First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer.]

▲▲ * Sunitinib malate for gastrointestinal stromal tumour (GIST) in imatinib mesylate resistant patients.
[National Guideline Clearinghouse | Sunitinib malate for gastrointestinal stromal tumour (GIST) in imatinib mesylate resistant patients.]

▲▲▲ * The continued use of trastuzumab beyond disease progression in patients with metastatic breast cancer.
[National Guideline Clearinghouse | The continued use of trastuzumab beyond disease progression in patients with metastatic breast cancer.]